Advanced targeted therapy for EGFR positive non small cell lung cancer with Tagrisso 80mg Tablet

A targeted tyrosine kinase inhibitor Tagrisso 80mg Tablet for non small cell lung cancer with EGFR positive mutation. It is prescribed as a first line treatment for metastatic disease, an adjuvant therapy after surgery, or for patients with the T790M mutation. Common side effects include diarrhea and rash, serious risks include lung inflammation and heart issues. To know more detailed information about the medication visit Globans Pharma website.